Loading...

Nanosonics

DB:OQS
Snowflake Description

Exceptional growth potential with flawless balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OQS
DB
A$1B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies. The last earnings update was 89 days ago. More info.


Add to Portfolio Compare Print
OQS Share Price and Events
7 Day Returns
-7.7%
DB:OQS
-1.6%
DE Medical Equipment
-3.2%
DE Market
1 Year Returns
61.3%
DB:OQS
13.5%
DE Medical Equipment
-11.6%
DE Market
OQS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Nanosonics (OQS) -7.7% -6.8% 19.7% 61.3% 90.9% -
DE Medical Equipment -1.6% 0.2% 5.3% 13.5% 101.9% 232.5%
DE Market -3.2% -5.1% 0.3% -11.6% 5.3% 5.9%
1 Year Return vs Industry and Market
  • OQS outperformed the Medical Equipment industry which returned 13.5% over the past year.
  • OQS outperformed the Market in Germany which returned -11.6% over the past year.
Price Volatility
OQS
Industry
5yr Volatility vs Market

OQS Value

 Is Nanosonics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Nanosonics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Nanosonics.

DB:OQS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:OQS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.89
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.892 (1 + (1- 30%) (0.06%))
0.928
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.928 * 5.96%)
5.76%

Discounted Cash Flow Calculation for DB:OQS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Nanosonics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:OQS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 5.76%)
2019 7.20 Analyst x2 6.81
2020 14.30 Analyst x2 12.79
2021 27.45 Analyst x2 23.21
2022 39.58 Est @ 44.19% 31.64
2023 51.85 Est @ 31% 39.19
2024 63.14 Est @ 21.77% 45.13
2025 72.81 Est @ 15.31% 49.20
2026 80.66 Est @ 10.78% 51.54
2027 86.80 Est @ 7.62% 52.44
2028 91.49 Est @ 5.4% 52.27
Present value of next 10 years cash flows A$364.20
DB:OQS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$91.49 × (1 + 0.23%) ÷ (5.76% – 0.23%)
A$1,658.00
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$1,658.00 ÷ (1 + 5.76%)10
A$947.15
DB:OQS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$364.20 + A$947.15
A$1,311.35
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$1,311.35 / 299.96
A$4.37
DB:OQS Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:OQS represents 0.6079x of ASX:NAN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.6079x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (AUD) x Listing Adjustment Factor
= A$ 4.37 x 0.6079
€2.66
Value per share (EUR) From above. €2.66
Current discount Discount to share price of €2.69
= -1 x (€2.69 - €2.66) / €2.66
-1.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Nanosonics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Nanosonics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Nanosonics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:OQS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.04
ASX:NAN Share Price ** ASX (2019-05-24) in AUD A$4.43
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 34.5x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 20.22x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Nanosonics.

DB:OQS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:NAN Share Price ÷ EPS (both in AUD)

= 4.43 ÷ 0.04

124.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nanosonics is overvalued based on earnings compared to the DE Medical Equipment industry average.
  • Nanosonics is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Nanosonics's expected growth come at a high price?
Raw Data
DB:OQS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 124.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
48.2%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.96x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

DB:OQS PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 124.65x ÷ 48.2%

2.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nanosonics is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Nanosonics's assets?
Raw Data
DB:OQS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.34
ASX:NAN Share Price * ASX (2019-05-24) in AUD A$4.43
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.13x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.76x
DB:OQS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:NAN Share Price ÷ Book Value per Share (both in AUD)

= 4.43 ÷ 0.34

13.07x

* Primary Listing of Nanosonics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nanosonics is overvalued based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Nanosonics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Nanosonics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

OQS Future Performance

 How is Nanosonics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
48.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Nanosonics expected to grow at an attractive rate?
  • Nanosonics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Nanosonics's earnings growth is expected to exceed the Germany market average.
  • Nanosonics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:OQS Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:OQS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 48.2%
DB:OQS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 25.1%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:OQS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:OQS Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-06-30 173 39 52 2
2021-06-30 131 28 32 4
2020-06-30 104 15 21 4
2019-06-30 81 8 10 4
DB:OQS Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 71 6 11
2018-09-30 66 8 8
2018-06-30 61 9 6
2018-03-31 61 11 6
2017-12-31 61 13 6
2017-09-30 64 15 16
2017-06-30 68 16 26
2017-03-31 65 16 26
2016-12-31 63 16 25
2016-09-30 53 10 13
2016-06-30 43 3 0
2016-03-31 33 -3 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Nanosonics's earnings are expected to grow significantly at over 20% yearly.
  • Nanosonics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:OQS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Nanosonics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OQS Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-06-30 0.18 0.19 0.16 2.00
2021-06-30 0.11 0.14 0.08 4.00
2020-06-30 0.07 0.08 0.06 4.00
2019-06-30 0.03 0.04 0.03 4.00
DB:OQS Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.04
2018-09-30 0.03
2018-06-30 0.02
2018-03-31 0.02
2017-12-31 0.02
2017-09-30 0.05
2017-06-30 0.09
2017-03-31 0.09
2016-12-31 0.09
2016-09-30 0.04
2016-06-30 0.00
2016-03-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Nanosonics is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Nanosonics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Nanosonics has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

OQS Past Performance

  How has Nanosonics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Nanosonics's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Nanosonics has delivered over 20% year on year earnings growth in the past 5 years.
  • Nanosonics's 1-year earnings growth exceeds its 5-year average (66.7% vs 46.2%)
  • Nanosonics's earnings growth has exceeded the DE Medical Equipment industry average in the past year (66.7% vs 3.2%).
Earnings and Revenue History
Nanosonics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Nanosonics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OQS Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 71.38 10.64 34.04 10.74
2018-09-30 66.04 8.20 33.36 10.31
2018-06-30 60.70 5.75 32.69 9.88
2018-03-31 61.05 6.07 30.97 9.88
2017-12-31 61.40 6.39 29.26 9.88
2017-09-30 64.45 16.27 28.40 9.68
2017-06-30 67.51 26.16 27.55 9.49
2017-03-31 65.42 25.76 26.37 8.89
2016-12-31 63.34 25.35 25.20 8.29
2016-09-30 53.07 12.74 25.28 7.79
2016-06-30 42.80 0.12 25.36 7.30
2016-03-31 33.12 -4.91 24.63 6.60
2015-12-31 23.45 -9.94 23.89 5.90
2015-09-30 22.83 -7.70 21.00 5.40
2015-06-30 22.21 -5.46 18.10 4.90
2015-03-31 24.18 -1.67 16.86 3.74
2014-12-31 26.15 2.12 15.61 2.57
2014-09-30 23.82 -0.25 16.09 1.58
2014-06-30 21.49 -2.61 16.57 0.59
2014-03-31 20.83 -2.91 15.49 0.58
2013-12-31 20.16 -3.22 14.42 0.57
2013-09-30 17.53 -4.50 14.13 0.51
2013-06-30 14.90 -5.77 13.84 0.46
2013-03-31 13.27 -6.73 13.77 0.44
2012-12-31 11.64 -7.70 13.70 0.42
2012-09-30 11.97 -6.19 12.55 0.40
2012-06-30 12.30 -4.68 11.39 0.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Nanosonics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Nanosonics used its assets more efficiently than the DE Medical Equipment industry average last year based on Return on Assets.
  • Nanosonics has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Nanosonics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Nanosonics has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

OQS Health

 How is Nanosonics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Nanosonics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Nanosonics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Nanosonics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Nanosonics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 134.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Nanosonics Company Filings, last reported 4 months ago.

DB:OQS Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 101.67 0.74 71.26
2018-09-30 101.67 0.74 71.26
2018-06-30 94.30 0.95 69.43
2018-03-31 94.30 0.95 69.43
2017-12-31 90.49 1.15 66.51
2017-09-30 90.49 1.15 66.51
2017-06-30 87.25 1.35 62.99
2017-03-31 87.25 1.35 62.99
2016-12-31 81.01 1.54 56.87
2016-09-30 81.01 1.54 56.87
2016-06-30 56.66 1.74 48.84
2016-03-31 56.66 1.74 48.84
2015-12-31 42.47 10.93 42.63
2015-09-30 42.47 10.93 42.63
2015-06-30 44.68 8.71 45.72
2015-03-31 44.68 8.71 45.72
2014-12-31 22.09 8.19 23.53
2014-09-30 22.09 8.19 23.53
2014-06-30 20.44 8.12 21.23
2014-03-31 20.44 8.12 21.23
2013-12-31 19.22 7.85 21.65
2013-09-30 19.22 7.85 21.65
2013-06-30 21.71 7.57 24.06
2013-03-31 21.71 7.57 24.06
2012-12-31 20.76 7.08 25.77
2012-09-30 20.76 7.08 25.77
2012-06-30 26.00 7.06 29.31
  • Nanosonics's level of debt (0.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (40.8% vs 0.7% today).
  • Debt is well covered by operating cash flow (839.1%, greater than 20% of total debt).
  • Nanosonics earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Nanosonics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Nanosonics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

OQS Dividends

 What is Nanosonics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Nanosonics dividends. Estimated to be 0% next year.
If you bought €2,000 of Nanosonics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Nanosonics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Nanosonics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:OQS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:OQS Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2022-06-30 0.00 1.00
2021-06-30 0.00 2.00
2020-06-30 0.00 2.00
2019-06-30 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Nanosonics has not reported any payouts.
  • Unable to verify if Nanosonics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Nanosonics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Nanosonics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Nanosonics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Nanosonics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Nanosonics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Nanosonics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

OQS Management

 What is the CEO of Nanosonics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Kavanagh
COMPENSATION A$1,119,151
TENURE AS CEO 5.6 years
CEO Bio

Mr. Michael C. Kavanagh, BSc, MBA (Advanced,) has been the Chief Executive Officer and President of Nanosonics Limited since October 21, 2013 and served as its Managing Director. Mr. Kavanagh served as a Senior Vice President of Global Marketing at Cochlear Limited. Mr. Kavanagh joined Cochlear in 2003. Has more than 20 years experience in the healthcare industry working in senior sales and marketing positions both locally and internationally within the pharmaceutical industry. He has been an Executive Director of Nanosonics Ltd since October 2013 and previously served as its Non-executive Director from July 2012 to October 2013. He holds a BSc (UCD Ireland) and an MBA advanced (Queensland).

CEO Compensation
  • Michael's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Michael's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Nanosonics management team in years:

1.7
Average Tenure
  • The average tenure for the Nanosonics management team is less than 2 years, this suggests a new team.
Management Team

Michael Kavanagh

TITLE
CEO, President
COMPENSATION
A$1M
TENURE
5.6 yrs

McGregor Grant

TITLE
CFO & Company Secretary
COMPENSATION
A$590K
TENURE
8.1 yrs

Steven Farrugia

TITLE
Chief Technology Officer
COMPENSATION
A$422K
TENURE
1.3 yrs

Rod Lopez

TITLE
Chief Operating Officer
TENURE
0.2 yrs

Renee Salaberry

TITLE
Chief Marketing Officer
TENURE
0.3 yrs

Leanne Baxendale

TITLE
Head of People & Culture
TENURE
2.2 yrs

Vincent Wang

TITLE
Head of Global Customer Support & Technical Services
COMPENSATION
A$202K

Ruth Cremin

TITLE
Head of Quality & Regulatory Affairs

Keith Koby

TITLE
Senior Vice President of Sales - North America
TENURE
2.6 yrs

David Morris

TITLE
Chief Strategy Officer & Regional President Asia Pacific
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Nanosonics board of directors in years:

8
Average Tenure
62
Average Age
  • The tenure for the Nanosonics board of directors is about average.
Board of Directors

Maurie Stang

TITLE
Non Executive Chairman of the Board
COMPENSATION
A$170K
TENURE
12.2 yrs

Michael Kavanagh

TITLE
CEO, President
COMPENSATION
A$1M
TENURE
6.8 yrs

Steve Sargent

TITLE
Non-Executive Deputy Chairman of the Board & Lead Independent Director
COMPENSATION
A$100K
AGE
58
TENURE
1.6 yrs

David Fisher

TITLE
Non-Executive Director
COMPENSATION
A$100K
TENURE
17.8 yrs

Richard Anthony England

TITLE
Non-Executive Director
COMPENSATION
A$100K
AGE
68
TENURE
9.3 yrs

Marie McDonald

TITLE
Non-Executive Director
COMPENSATION
A$85K
AGE
62
TENURE
2.6 yrs
Who owns this company?
Recent Insider Trading
  • Nanosonics insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
06. May 19 Sell Morgan Stanley, Investment Banking and Brokerage Investments Company 23. Apr 19 02. May 19 -5,738,122 €3.11 €-17,863,543
06. May 19 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 23. Apr 19 02. May 19 2,776,810 €3.03 €8,412,167
30. Apr 19 Sell David Fisher Individual 26. Apr 19 26. Apr 19 -40,000 €2.89 €-115,477
23. Apr 19 Sell Morgan Stanley, Investment Banking and Brokerage Investments Company 30. Jan 19 17. Apr 19 -195,122 €2.41 €-469,963
23. Apr 19 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 30. Jan 19 17. Apr 19 153,745 €2.62 €402,690
23. Apr 19 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 18. Apr 19 18. Apr 19 96,178 €2.84 €273,063
03. Mar 19 Sell Maurie Stang Individual 01. Mar 19 01. Mar 19 -1,250,000 €2.59 €-3,237,401
26. Feb 19 Sell Michael Kavanagh Individual 26. Feb 19 26. Feb 19 -310,000 €2.64 €-817,113
01. Feb 19 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 10. Jan 18 29. Jan 19 12,937,627 €2.04 €25,713,422
23. Nov 18 Sell JCP Investment Partners Limited Company 02. Oct 18 21. Nov 18 -1,287,104 €1.98 €-2,343,223
25. Oct 18 Sell JCP Investment Partners Limited Company 23. Jun 18 23. Oct 18 -6,760,164 €2.13 €-14,394,264
25. Oct 18 Buy JCP Investment Partners Limited Company 23. Jun 18 23. Oct 18 3,933,414 €1.95 €7,677,642
03. Oct 18 Sell JCP Investment Partners Limited Company 26. Sep 18 01. Oct 18 -669,800 €2.27 €-1,498,556
27. Sep 18 Buy JCP Investment Partners Limited Company 21. Sep 18 25. Sep 18 1,133,914 €1.92 €2,173,694
25. Sep 18 Sell JCP Investment Partners Limited Company 16. Aug 18 20. Sep 18 -1,193,400 €2.37 €-2,743,890
25. Sep 18 Buy JCP Investment Partners Limited Company 16. Aug 18 20. Sep 18 1,266,700 €2.18 €2,620,934
13. Sep 18 Sell David Fisher Individual 13. Sep 18 13. Sep 18 -50,000 €2.01 €-100,531
27. Aug 18 Sell Maurie Stang Individual 24. Aug 18 24. Aug 18 -43,640 €2.32 €-101,393
17. Aug 18 Sell JCP Investment Partners Limited Company 03. Aug 18 15. Aug 18 -3,175,391 €2.20 €-6,784,651
06. Aug 18 Sell JCP Investment Partners Limited Company 13. Jun 18 02. Aug 18 -3,455,784 €2.10 €-3,760,960
14. Jun 18 Sell JCP Investment Partners Limited Company 25. May 18 12. Jun 18 -3,322,200 €2.01 €-6,539,526
14. Jun 18 Buy JCP Investment Partners Limited Company 25. May 18 12. Jun 18 190,131 €1.71 €325,714
X
Management checks
We assess Nanosonics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Nanosonics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

OQS News

Simply Wall St News

OQS Company Info

Description

Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies. The company manufactures and distributes the trophon EPR ultrasound probe disinfector for use in the treatment of healthcare acquired infections. It also provides trophon2, an ultrasound probe high level disinfection device. In addition, the company offers trophon EPR and trophon2 consumables and accessories, including NanoNebulant cartridges; chemical indicators; trophon printers, logbooks, connect products, and clean ultrasound probe covers; trophon wall mounts, carts, printer wall mounts, printer cart mounts, and curved probe positioners; trophon AcuTrace operator cards and medical instrument tags; trophon printer USB cables and label rolls; trophon AcuTrace PLUS activation cards; and cleaning and drying wipes. It operates in Australia, North America, Europe, and the Asia Pacific. The company was incorporated in 2000 and is headquartered in Lane Cove, Australia.

Details
Name: Nanosonics Limited
OQS
Exchange: DB
Founded: 2000
A$819,963,081
299,962,256
Website: http://www.nanosonics.com.au
Address: Nanosonics Limited
14 Mars Road,
Lane Cove,
New South Wales, 2066,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX NAN Ordinary Shares Australian Securities Exchange AU AUD 17. May 2007
OTCPK NNCS.F Ordinary Shares Pink Sheets LLC US USD 17. May 2007
DB OQS Ordinary Shares Deutsche Boerse AG DE EUR 17. May 2007
CHIA NAN Ordinary Shares Chi-X Australia AU AUD 17. May 2007
Number of employees
Current staff
Staff numbers
225
Nanosonics employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/24 21:06
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/02/26
Last earnings filing: 2019/02/24
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.